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Abstract
Epidemiology studies suggested that low birthweight was associated with a higher risk of 
hypertension in later life. However, little is known about the causality of such associations. In our 
study, we evaluated the causal association of low birthweight with adulthood hypertension 
following a standard analytic protocol using the study-level data of 183,433 participants from 60 
studies (CHARGE-BIG consortium), as well as that with blood pressure using publicly available 
summary-level genome-wide association data from EGG consortium of 153,781 participants, 
ICBP consortium and UK Biobank cohort together of 757,601 participants. We used seven SNPs 
as the instrumental variable in the study-level analysis and 47 SNPs in the summary-level analysis. 
In the study-level analyses, decreased birthweight was associated with a higher risk of 
hypertension in adults (the odds ratio per 1 standard deviation (SD) lower birthweight, 1.22; 95% 
CI 1.16 to 1.28), while no association was found between genetically instrumented birthweight 
and hypertension risk (instrumental odds ratio for causal effect per 1 SD lower birthweight, 0.97; 
95% CI 0.68 to 1.41). Such results were consistent with that from the summary-level analyses, 
where the genetically determined low birthweight was not associated with blood pressure 
measurements either. One SD lower genetically determined birthweight was not associated with 
systolic blood pressure (β = −0.76, 95% CI —2.45 to 1.08 mmHg), 0.06 mmHg lower diastolic 
blood pressure (β = −0.06, 95% CI −0.93 to 0.87 mmHg), or pulse pressure (β = −0.65, 95% CI 
−1.38 to 0.69 mmHg, all p > 0.05). Our findings suggest that the inverse association of birthweight 
with hypertension risk from observational studies was not supported by large Mendelian 
randomization analyses.
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Hypertension, defined as high in systolic blood pressure, diastolic blood pressure, or both 
above normal levels, is a leading risk factor for mortality and morbidity. In 2015, high 
systolic blood pressure was associated with the heaviest disease burden among risk factors—
more than either smoking or obesity [1]. Worldwide, the estimated rate of death attributable 
to high systolic blood pressure (140 mmHg or more) was 106.3/100,000 persons in 2015, 
and the number of disability-adjusted life-years was 7.8 million [2].
Over the past decades, epidemiology studies have provided emerging observational evidence 
for developmental origins for hypertension [3]. Low birthweight, a surrogate marker of 
intrauterine malnutrition and developmental stressors, has emerged as a potential risk factor 
for cardiometabolic disorders, including hypertension in later life [4, 5]. Several lines of 
pathophysiological evidence have provided potential mechanisms including vascular 
dysfunction, reduced nephron numbers, sympathetic activation and neuroendocrine involved 
in the association of low birthweight with adulthood hypertension and blood pressure [6]. 
However, conventional observational studies are vulnerable to serious issues of confounding, 
reverse causality, inappropriate adjustment of current weight, and therefore are not able to 
make causal inference. Large-scaled meta-analyses of the observed associations between 
birthweight and hypertension in later life had reached controversial conclusions [5, 7]. 
Traditional clinical trials are unrealistic in such cases to assess the causality of these 
associations, necessitating other study designs.
Mendelian randomization (MR) is an emerging approach which takes advantage of genetic 
markers as instrumental variables (IVs) and therefore, potentially overcomes the limitations 
as mentioned above of observational studies and clinical trials. This approach exploits the 
fact that at meiosis individual genotypes are assigned randomly, and therefore, the effect of 
genetics on disease is free of confounding or reverse causality [8]. Birthweight has a 
significant genetic architecture, and approximately 15% of its variance can be attributed to 
fetal genetic variation [9], although the intrauterine environment also has considerable 
influence. Recent genome-wide association studies (GWAS) have identified seven variants 
[10] associated with birthweight, and such a list has expanded to 60 loci where fetal 
genotype was associated with birthweight [9]. These genetic variants can be used as a proxy 
for birthweight to examine whether low birthweight contributes causally to hypertension 
development.
In this study, we collected extensive study-level data from 60 studies with 183,433 
participants (CHARGE-BIG consortium) and summary-level data from the Early Growth 
Genetics (EGG) consortium of 153,781 participants, the International Consortium of British 
Pensioners (ICBP) consortium and UK Biobank cohort (UKB) together of 757,601 
participants, and explored the possible causal association of birthweight with adulthood 
blood pressure and hypertension using MR analyses. Because our study started earlier than 
the most recent published GWAS, which reported 60 loci of birthweight, we included the 
previous seven variants as the instrument variables in the analysis of study-level data, and 57 
loci of birthweight in the analysis of summary-level data.
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Study design and instruments
We use MR analyses to assess the causal association of birthweight with blood pressure and 
hypertension risk, under three assumptions [11]. First, genetic variants used as an instrument 
must be associated with birthweight. Second, genetic variants must not be associated with 
confounders. Third, genetic variants must not be associated with hypertension or blood 
pressure independent of birthweight. The above-mentioned second and third assumptions 
jointly refer to independence from pleiotropy.
This study consisted of two parts (Fig. 1). First, we estimated the causal association of birth 
weight with hypertension risk using study-level data from the Cohorts for Heart and Aging 
Research in Genomic Epidemiology-Birth Gene (CHARGE-BIG) Study, which included 60 
cross-sectional and prospective cohort studies with a total of 180,056 participants. The 
details of CHARGE-BIG study have been described before [12]. In brief, we analyzed the 
data within each study by standardized analytic methods using a genetic risk score (GRS) of 
the 7 single-nucleotide polymorphisms (SNPs) as an IV from an earlier GWAS of the EGG 
Consortium [10]. Second, we explored the causal association of birth weight with systolic 
blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure (PP) utilizing 
summary-level data from the EGG consortium (n = 153,781) [9], the UKB (n = 458,577) 
and the ICBP consortium (n = 299,024) [13]. Because neither UKB nor ICBP has 
hypertension as an existing categorical outcome in GWAS summary data, we included blood 
pressure measurements as the outcome variables in the summary-level analysis. A total of 
the available 57 SNPs or its proxies, a subset of the 60 SNPs reported by an updated result 
of EGG consortium [9], were used as the instrument for birth weight in the summary-level 
analysis.
All participants from CHARGE-BIG consortium provided written informed consent, and all 
participating studies received approval from local research ethics committees. The appendix 
(Supplemental Table 1) includes the description of all the included studies in CHARGE-BIG 
consortium in the analysis. Contributing studies received ethical approval from their 
respective institutional review boards.
Phenotypic measures
In the CHARGE-BIG consortium, Hypertension was defined as systolic blood pressure of 
140 mmHg or higher, diastolic blood pressure of 90 mmHg or higher, or current use of 
antihypertensive medication. Birthweight was self-reported or collected from medical 
records, and information of covariates was collected in each study. The appendix 
(Supplemental Table 2) describes details about the methods used to collect information on 
birthweight and hypertension in each study. The detailed genome-wide analysis of blood 
pressure traits, including SBP, DBP and PP, among participants of European ancestry from 
UKB [14] and ICBP consortium [15, 16] have been described previously [13].
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Selection of SNPs and genetic risk scores
In the study-level analyses, to create the GRS of low birthweight we selected 7 SNPs 
(CCNL1 rs900400, ADCY5 rs9883204, HMGA2 rs1042725, CDKAL1 rs6931514, 5q11.2 
rs4432842, LCORL rs724577, ADRB1 rs1801253) based on findings from 69,308 
participants of European descent by the EGG Consortium [10]. The genotyping information 
and the distribution of genotypes of these 7 SNPs in each study were described in 
Supplemental Tables 3 and 4. In a secondary analysis, we excluded 5 SNPs associated with 
blood pressure or significant confounders such as adult height and type 2 diabetes [10], and 
included the rest two SNPs in the GRS. We constructed an externally weighted low 
birthweight GRS, weighted by the effect estimates reported in EGG GWAS (β is the change 
in z score of birthweight per birthweight-lowering allele from linear regression, adjusted for 
sex and gestational age where available, assuming an additive genetic model) [10].
For the summary-level data analysis, a total of 60 SNPs were reported to be associated with 
birth weight by a more recent report from EGG consortium [9], of which 50 were available 
in UKB and ICBP consortium. For those SNPs that were not genotyped, we found proxies 
that are in high linkage disequilibrium with the corresponding SNP (r2 > 0.8) according to 
the information from 1000 Genomes Project. Ultimately, 57 SNPs were used as the 
instrument to assess the causal association of birth weight with blood pressure 
measurements.
Statistical analysis
Study-level analyses—In the study-level analyses, each of the CHARGE-BIG studies 
analyzed the data following a standard analytic protocol. Generalized linear regression 
models of the association between GRS and hypertension were adjusted with age, sex, body 
mass index (BMI), total energy intake, and principal components for population 
stratification if available. With respect to the phenotypic analyses, logistic regression models 
with hypertension as outcome and birthweight as exposure were adjusted with age, sex, 
BMI, and other risk factors of hypertension if available, such as smoking status (current vs. 
former/never), physical activity (MET h/day or hours) (quintiles), total energy intake (kcal) 
(quintiles), and alcohol consumption (quintiles). Concerning the genetic effects on 
birthweight, the effect allele was the birthweight-lowering allele, as established by the EGG 
consortium [10]. We tested for association of the GRS with birthweight using linear 
regression models, adjusting for sex, gestational age if available, and principal components 
for population stratification if available.
Within the CHARGE-BIG collaboration, formal MR analyses were conducted using the IV 
ratio method [17]. To assess the IV ratio for the effect of birthweight on hypertension, we 
divided the meta-analyzed association of birthweight GRS with hypertension by the 
association of birthweight GRS with birthweight. The variance for the IV ratio was 
estimated using a Taylor expansion. [18] The above analyses were repeated in the sex- and 
BMI (< 25 kg/m2, or ≥ 25 kg/m2)-stratified subgroups. To examine the strength of the GRS 
as an instrument, we calculated the F-statistic from the proportion of variation in the 
birthweight (R2) explained by the allele score, controlling for covariates (age, sex, and 
principal components for population stratification) in the Nurses’ Health Study (NHS) and 
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the Health Professionals Follow-Up Study (HPFS) cohorts. An F statistic greater than 10 is 
evidence of a strong instrument [19].
To examine whether the SNPs for birthweight were associated with potential confounders, 
each birthweight-associated SNP was evaluated for pleiotropy associations with potential 
risk factors, including major lipids in 196,476 individuals (Global Lipids Genetics 
Consortium) [20], glycemic traits in 46,186 individuals without diabetes (Meta-Analyses of 
Glucose and Insulin-Related Traits Consortium) [21], type 2 diabetes in 110,452 individuals 
(Diabetes Genetics Replication and Meta-analysis) [22], BMI and waist-to-hip ratio adjusted 
for BMI in 224,459 individuals (Genetic Investigation of Anthropometric Traits) [23], and 
chronic kidney disease-defining traits in 175,579 individuals [24] (Supplemental Fig. 1).
In the presence of heterogeneity of association among studies, inverse variance-weighted 
random-effects models were used for meta-analyses; otherwise, fixed-effects models were 
used. Heterogeneity among studies was assessed with the I2 statistic.[25–27] We found non-
negligible heterogeneity between studies, in particular among the birthweight-hypertension 
associations, but also for the association between low birthweight GRS and birthweight (I2 > 
0.25).
Summary-level analyses
We extracted 57 beta-coefficients and standard errors of the SNP-birthweight associations 
from EGG consortium, and that of SNP-blood pressure associations from the ICBP 
consortium and UKB via GWAS catalog (https://www.ebi.ac.uk/gwas/downloads/summary-
statistics). We computed individual MR estimates and standard errors by weighting the 
effect sizes based on the magnitude of the SNP-birthweight association [28]. We used the 
inverse variance-weighted (IVW) MR approach as the primary analysis, where the inverse 
variance weighted mean of ratio estimates from the multiple IVs is the IV estimate [28]. 
This approach assumes that IVs affect the outcome only through the exposure under 
consideration, and not via any alternative pathways [28]. Violation of this assumption 
implies horizontal pleiotropy of the IV, measured by the heterogeneity estimates of Cochran 
Q-derived p < 0.05, and it could bias the MR estimate. Thus, we further conducted several 
sensitivity analyses with different assumptions regarding the presence of pleiotropic genetic 
variants that may relate with the outcome independently of the exposure. For example, MR-
Egger regression requires that the strengths of the instruments are independent of their direct 
associations with the outcome [11], and the weighted median method requires that at least 
half of the information for the MR analysis comes from valid instruments [29]. The intercept 
of the MR-Egger regression is a measure of directional pleiotropy (p < 0.05 was considered 
significant) [11].
We carried out all the analyses with R version 3.2.3 (https://www.r-project.org).
Results
The study-level results
In the study-level analysis, the analytic sample included 183,433 individuals from 60 cohort 
and case—control studies (Fig. 2, Supplemental Table 5). Twenty-four studies (51,568 
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participants) reported the GRS-birthweight associations; and 33 studies 
(109,735participants) reported the GRS-hypertension associations. A total of 70,874 
hypertensive participants and 61,933 normotensive controls provided hypertension-related 
data, and 50,626 participants provided GRS-birthweight associations only. The majority of 
participants were of European (86%) and Asian (14%) ancestry (Supplemental Table 5).
Large scale GWAS consortia did not suggest that the seven SNPs were associated with 
potential hypertension risk factors, including circulating major lipids, fasting glucose and 
insulin, type 2 diabetes, BMI, waist-to-hip ratio, and chronic kidney disease (Supplemental 
Fig. 1). The low birthweight GRS was inversely associated with birthweight (Fig. 3a, each 
risk allele was associated with 0.02 standard deviation (SD) lower birthweight, and there 
was evidence for heterogeneity in such an association (I2 = 78%, p < 0.01). The F-statistics 
for the score were both > 18 using data from the NHS and the HPFS (Supplemental Table 
6), indicating the GRS is a strong composite instrument.
In the meta-analysis of the CHARGE-BIG studies, lower birthweight was associated with a 
higher risk of hypertension in adults (Table 1 and Fig. 4, odds ratio (OR) per 1 SD lower 
birthweight, 1.22, 95% CI 1.16 to 1.28). There was no significant association of the low 
birthweight GRS with hypertension risk (Table 1 and Fig. 3b, OR per 1 risk allele of low 
birthweight: 1.00, 95% CI 0.99 to 1.01). The relationships of lower birthweight and low 
birthweight GRS with the risk of hypertension in both sexes and BMI status were consistent 
with those in the overall population (Table 1).
In the formal MR analysis, genetically instrumented birthweight was not associated with risk 
of hypertension (Table 1 and Fig. 4, instrumental OR for causal effect per 1 SD lower 
birthweight: 0.97, 95% CI 0.68 to 1.41). Again, no association was seen in each sex or BMI 
status group (Table 1). The secondary analysis using two SNPs conservatively either showed 
no association between genetically instrumented birthweight and risk of hypertension 
(instrumental OR 1.12, 95% CI 0.66 to 1.89, Supplemental Fig. 2).
The summary-level results
In the random-effect IVW MR analyses using the 57 SNPs as the IVs, one SD lower 
genetically instrumented birth weight showed a trend of association with 0.76 mmHg lower 
SBP (95% CI — 2.45 to 1.08 mmHg), 0.06 mmHg lower DBP (95% CI — 0.93 to 0.87 
mmHg), and 0.65 mmHg lower PP (95% CI 95% CI — 1.38 to 0.69 mmHg), however, none 
of these associations was significant (all p > 0.05, Table 2). No presentation for directional 
pleiotropy effects was detected by the MR-Egger intercept (SBP, p = 0.73; DBP, p = 0.64; 
PP, p = 0.90; Table 2). Although there was evidence for horizontal pleiotropy of the IV 
(Cochran Q derived p < 0.05), the results from MR-Egger method and weighted median 
based method were consistent with that from IVW MR method for SBP, DBP and PP (Table 
2). We further excluded 14 previously reported SNPs for blood pressure or hypertension, or 
used the 7 SNPs only as sensitivity analyses in order to be consistent with the study-level 
analyses, and in either situation low birthweight remained not associated with blood pressure 
measurements (Supplemental Table 7).
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Numerous nutritional interventions have been effective in reducing the short-term risk of low 
birthweight and prematurity. Understanding the potential long-term benefits of such 
interventions is crucial to inform policy decisions to interrupt the developmental 
programming cycle and stem the growing epidemics of hypertension worldwide. With low 
birthweight related genetic loci as the IV, the results of our MR analysis provide evidence 
for a non-causal effect of low birthweight on a higher risk of hypertension and blood 
pressure measurements, suggesting that low birthweight might not be a casual risk factor for 
development of hypertension.
Evidence from observational studies of low birthweight and a higher risk of hypertension 
constitutes some most robust finding supporting the fetal origins of adult disease [30]. 
Barker et al. were the first to report that low birthweight was associated with a higher risk of 
cardiovascular disease [31]. Subsequently, Brenner and colleagues proposed that 
developmental programming in the kidney may reduce nephron number, which may result in 
a limited filtration surface area and reduced sodium excretion, and eventually development 
of hypertension [32]. Our observed inverse association of birthweight with hypertension risk 
was consistent with traditional observational studies, which were largely from Caucasians 
[4, 33–36]. In Chinese populations, intrauterine exposure to famine was related to a higher 
risk of hypertension in adults [37, 38], and such findings were indirectly consistent with our 
observational findings.
In our study, we did not observe an association of genetically determined birthweight with 
hypertension risk or blood pressure measurements during adulthood. Our result is in line 
with that from the recent MR analysis from UKB [39], which also reported a null 
association of birthweight with blood pressure and hypertension risk. However, the UKB 
analysis exclusively studied the Caucasian population in the UK, and our analysis included 
samples of Caucasians and Asians from diverse populations and countries. It is worth 
mentioning the genetic correlation analyses of birthweight with hypertension from the recent 
GWAS for birthweight [9]. This GWAS is in line with our findings that it suggested a lack of 
genetic association between birthweight and blood pressure from linkage-disequilibrium 
score regression, indicating that birthweight is not causal for hypertension risk and blood 
pressure as well. Consistently, a recent MR study with a smaller sample size (n = 5000) 
selecting instruments according this GWAS did not found significant causal association 
between birth weight and hypertension either [40, 41]. Our study suggested a lack of 
association of the genetic instruments of birthweight, and this observation did not implicate 
that a lack of association of the intrauterine malnutrition and developmental stressors with 
hypertension risk. It is possible that the environment determined lower birth weight might 
have an effect on the risk of hypertension, though it is beyond the scope of the current 
analysis. Our findings should not be interpreted as to undermine the critical value of 
interventions improving birthweight in order to lower the hypertension risk in later life.
Our study has several strengths. First, we carried out an IV analysis on the causality of 
birthweight on hypertension and blood pressure using large and diverse populations. The 
large sample size might provide us with sufficient power to estimate the causal effect of low 
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birthweight on hypertension and blood pressure, and the diverse source of data allows decent 
generalizability. Second, we used a standardized analysis protocol to collect study-level 
statistics within CHARGE-BIG consortium, and it minimized the potential bias from 
different data analyses methods. Our data should be interpreted with caution, and several 
limitations were related to the validity of the assumptions underlying the causal 
interpretation of MR studies. First, for the instrument variable, in the study-level analyses 
we only used seven SNPs related with low birthweight instead of the 60 SNPs from the most 
recent GWAS [9], however, in our summary-level analyses, we included 57 available SNPs. 
The results were consistent in study-level and summary-level analyses, as well as in different 
sensitivity analyses, providing further support for the noncausal association of birthweight 
with blood pressure and hypertension risk. Second, though we have minimized the 
horizontal pleiotropic effects using exiting large consortia data and different MR sensitivity 
analysis methods, future studies are warranted to take into consideration other essential 
factors that may be causatively related with intrauterine growth restriction. Such factors may 
include prenatal factors such as gestational week and postnatal behaviors such as 
breastfeeding. Third, we did not include the maternal genetic background in the analysis, 
which may affect the intrauterine environment and therefore, birthweight. Recent GWAS 
suggested that several maternal genetic variants influence fetal birthweight independently of 
the fetal genome [42]. Therefore, future MR studies with IVs from both maternal and fetal 
aspects of adult hypertension risk and blood pressure would provide new insights. Fourth, 
we did not collect blood pressure measurements from individual studies in the study-level 
analysis. Blood pressure may have a more significant measurement error, and the estimated 
association with blood pressure may be weaker compared that with hypertension [43]. 
Nevertheless, we used the blood pressure measurements in the summary-level analyses and 
reached consistent conclusion. Fifth, in the study-level analyses, we defined hypertension 
according to the previous definition [44] not the one currently proposed [45] by the 
American Heart Association, as the study was designed and conducted before the new 
definition issued. Canalization is one possible explanation for our results, because the low 
birthweight allele score might have led to biological adaptations during development [8]. 
Furthermore, we assumed that the association of genetically determined birthweight with 
hypertension risk and blood pressure is linear; however, such assumption may not be correct 
because both the extreme low or high birthweights influence hypertension risk [46].
The associations of low birthweight, as an indicator of intrauterine growth restriction, with a 
higher hypertension risk and blood pressure measurements in adults from observational 
studies were not supported by our MR analyses. These findings suggest that the 
observational association of birthweight with hypertension risk in later life could be the 
result of confounding.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Study design. The data sources included study-level data from the Cohorts for Heart and 
Aging Research in Genomic Epidemiology-Birth Gene (CHARGE-BIG) Study, which 
included 60 cross-sectional and prospective cohort studies, and summary-level data from the 
Early Growth Genetics (EGG) consortium, International Consortium of British Pensioners 
(ICBP) consortium and UK Biobank
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Flow chart showing the sample sizes available at each stage of the meta-analyses in 
CHARGE-BIG consortium
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Meta-analysis of associations of low birth weight genetic risk score with birth weight (a) and 
hypertension (b) using the study-level data from CHARGE-BIG consortium. Betas were the 
associations of low birth weight genetic risk score with outcome, per risk allele for low birth 
weight. CI, confidence interval
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Mendelian Randomization triangulation for hypertension using study-level data from 
CHARGE-BIG consortium. IV instrumental variable, OR odds ratio, CI confidence interval
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Table 2
Mendelian randomization of birth weight with blood pressure using summary level data from EGG 
consortium, ICBP consortium and UK Biobank cohort
βa (95% CI) p-value
Systolic blood pressure (mmHg)
 Inverse variance weighted method −0.76 (−2.45, 1.08) 0.40
 Weighted median based method −0.37 (−0.77, 0.52) 0.33
 MR-Egger method −1.78 (−2.09, 0.10) 0.56
 MR-Egger regression
b 0.03 (−0.17, 0.18) 0.73
Diastolic blood pressure (mmHg)
 Inverse variance weighted method −0.06 (−0.93, 0.87) 0.89
 Weighted median based method −0.28 (−0.52, 0.39) 0.22
 MR-Egger method −0.77 (−4.20, 1.83) 0.62
 MR-Egger regression
b 0.02 (−0.10, 0.10) 0.64
Pulse pressure (mmHg)
 Inverse variance weighted method −0.65 (−1.38, 0.69) 0.23
 Weighted median based method 0.05 (−0.55, 0.58) 0.86
 MR-Egger method −0.87 (−5.07, 1.95) 0.63
 MR-Egger regression
b 0.01 (−0.10, 0.10) 0.90
a
β represents the effect size of 1 – SD lower genetically instrumented birth weight on systolic blood pressure, diastolic blood pressure, and pulse 
pressure
b
Intercept of MR Egger regression, which is a measure of directional pleiotropy (p < 0.05 was considered significant)
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